European Journal of Molecular & Clinical Medicine

To evaluate the effect of uncomplicated phacoemulsification on central macular thickness (CMT) and best corrected visual acuity (BCVA) in diabetic patients without diabetic retinopathy (DR) and diabetic patients with mild to moderate non proliferative diabetic retinopathy (NPDR).
Materials & methods: A total of 200 diabetic patients (200 eyes) who underwent phacoemulsification were divided into 2 groups as Group A:100 patients withoutDR and Group B:100 patients with mild to moderate NPDR. All patients entered into the study were followed up preoperatively and at 1 month, 6 months and 1 year after phacoemulsification and CMT and BCVA were evaluated at each follow up and tabulated and analyzed by suitable statistical tests.
Results: CMT of group A at postoperative 1 month and 6 months was 259.20±20.57µm and 243.48±11.11µm respectively and of group B was 280.03±34.52µm and 254.28±16.46µm respectively. There was significant difference between 2 groups at both postoperative 1 month and 6 months after uncomplicated phacoemulsification. There was no significant difference in the postoperative mean CMT at 1 year between group A (234.03±9.38µm) and group B (240.21±34.00 µm). Mean BCVA Log MAR was 0.15±0.22 in group A as compared to 0.30±0.34 in group B at postoperative 1 month, mean BCVA Log MAR was 0.13±0.12 in group A as compared to 0.20±0.20 in group B at postoperative 6 months, mean BCVA Log MAR was 0.11±0.11 in group A as compared to 0.17±0.15 in group B at postoperative 1 year. ‘p’-value was highly significant in the mean BCVA Log MAR at postoperative at 1 month,6 months and 1 year between the two groups.
Conclusion: There was significant increase in mean CMT and mean BCVA Log MAR at postoperative 1 month,6 months and 1 year in both the groups. At postoperative 1 and 6 months there was significant difference in CMT between both groups whereas there was no significant difference in CMT at 1 year between the 2 groups. At postoperative 1 month, 6 months and 1 year, there was significant difference in BCVA Log MAR between both groups.

Aim: To compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and healthy subjects.
Material & Methods: This is a prospective study, carried out on 92 patients. The patients were divided in to two groups: study group included 50 patients and control group comprised of 42 patients.
Results: The mean HbA1c level was 8.68 ± 2.39% in the study group and 5.10 ± 0.76% in the control group. The mean level of HbA1c was statistically higher in the study group than in the control group (Table 1, P = 0.001). Fasting plasma glucose level was statistically higher in the study group than in the control group (P= 0.001).
Conclusion: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects

Background: Diabetic macular edema (DME) has been reported at rates of 10% and occurs more frequently in type 2 diabetes mellitus. The present study was conducted to assess the efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Materials & Methods: 60 patients with type 2 diabetes having treatment naïve, center‑involving DME of both genders were divided into 2 groups.  Group I had DME only in one eye and group II had DME in both eyes. Group I were given oral fenofibrate 160 mg/day for 6 months as a single evening dose. Central macular thickness in both groups was compared.
Results: The mean FBS was 137.6 mg/dl in group I and 158.2 mg/dl in group II, PPBS was 210.4 mg/dl and 238.6 mg/dl, blood urea (mg/dl) was 29.3 in group I and 31.5 in group II and serum creatinine (mg/dl) was 0.92 and 0.99 in group I and in group II respectively. CMT in group I and group II at baseline was 432.6 and 402.1, at 2 months was 360.2 and 358.1, at 4 months was 327.5 and 331.4 and at 6 months was 294.3 and 317.6 in group I and in group II respectively. The difference was non- significant (P>0.05).
Conclusion: Fenofibrate facilitate reduction of central macular thickness in patients with diabetic macular edema